PDCD1 and melanoma: Notably, in melanoma, while CTLA-4 blockade with ipilimumab was the first treatment to extend overall survival in patients with advanced melanoma in a randomized setting, anti-PD-1 mAb treatment (nivolumab) demonstrated higher efficacy in patients with smaller tumors (7, 91–94).